Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 27,708 shares at $1.69 ($47K) on 2022-03-01, disclosed to the SEC on 2022-03-03.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| OTLK | BUY | 2022-10-03 | $163K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |
| OTLK | BUY | 2022-02-23 | $514K | — | Filing → |